相关实验视频

Updated: Jun 27, 2025

Porcine Model of Infrarenal Abdominal Aortic Aneurysm
11:13

Porcine Model of Infrarenal Abdominal Aortic Aneurysm

Published on: November 21, 2019

9.4K

在患有上升性大动脉动脉瘤患者使用Pembrolizumab的预防性说明

Muhammad E A Khan1, Shane Ahern1, Sophie C Prendergast2

  • 1Department of Cardiothoracic Surgery, Cork University Hospital, Cork, Ireland.

European journal of case reports in internal medicine
|May 8, 2024
PubMed
概括

免疫检查点抑制剂,如 pembrolizumab,可以导致由于主动脉炎导致主动脉动脉瘤迅速扩张. 患有先前存在的动脉瘤的患者需要在此疗法期间保持警的监测.

关键词:
免疫检查点抑制剂 免疫检查点抑制剂一个aortitis的炎症上升的大动脉动脉瘤.黑色素瘤是一种黑色素瘤.这就是Pembrolizumab.

更多相关视频

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound10:09

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound

Published on: August 4, 2022

3.2K
Quantitative Micro-CT Analysis of Aortopathy in a Mouse Model of β-aminopropionitrile-induced Aortic Aneurysm and Dissection06:46

Quantitative Micro-CT Analysis of Aortopathy in a Mouse Model of β-aminopropionitrile-induced Aortic Aneurysm and Dissection

Published on: July 16, 2018

9.6K

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
155
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157